<DOC>
	<DOCNO>NCT00413959</DOCNO>
	<brief_summary>Overall response rate Time disease progression use regimen patient low-grade B-Cell Non-Hodgkin 's Lymphoma .</brief_summary>
	<brief_title>VELCADEÂ® , Rituximab , Cyclophosphamide Decadron ( VRCD Regimen )</brief_title>
	<detailed_description>This phase II open label study look VRCD combination regimen patient previously untreated low-grade Non-Hodgkin 's Lymphoma . Treatment start combine oral dexamethasone cyclophosphamide intravenous VELCADE , rituximab . Chemotherapy cycle give outlined every 35-days continue two cycle beyond complete remission ( CR ) , toxicity , patient 's withdrawal , disease progression , maximum 8 cycle .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Small Lymphocytic Lymphoma Follicular Cell Lymphoma ( grade I II ) Mantle Cell Lymphoma patient consider eligible highdose therapy stem cell transplant Lymphoplasmacytic lymphoma include Waldenstrom 's Macroglobulinemia Marginal Zone Lymphoma MALT Lymphoma ONLY fail antibiotic therapy involve field radiation . Adequate bone marrow function , renal function , hepatic function outline detail . ECOG performance status 0 , 1 , 2 Able read , understand , sign IRB approve informed consent Known HIV positive status Known CNS involvement Prior therapy lymphoma EXCLUDING antibiotic treatment MALTType NHL .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>NHL</keyword>
</DOC>